致编辑的信：关于“糠酸氟替卡松/乌美溴铵/维兰特罗（FF/UMEC/VI）三联疗法与其他疗法治疗慢性阻塞性肺疾病的网络荟萃分析” - Suppr

Suppr

超能文献

Letter to the Editor Regarding "Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Triple Therapy Compared with Other Therapies for the Treatment of COPD: A Network Meta-Analysis".

作者信息

Marshall Jonathan, Sharma Akanksha, Darken Patrick, Ouwens Mario, Singh Barinder, Tansey-Dwyer Deniz

机构信息

AstraZeneca, Academy House, 136 Hills Road, Cambridge, CB2 8PA, UK.

Pharmacoevidence, Mohali, PB, India.

出版信息

Adv Ther. 2023 May;40(5):2549-2555. doi: 10.1007/s12325-023-02491-4. Epub 2023 Apr 1.

DOI:10.1007/s12325-023-02491-4

PMID:37004641

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10129921/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5213/10129921/40cc00b8f99f/12325_2023_2491_Fig1_HTML.jpg

相似文献

Letter to the Editor Regarding "Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Triple Therapy Compared with Other Therapies for the Treatment of COPD: A Network Meta-Analysis".致编辑的信：关于“糠酸氟替卡松/乌美溴铵/维兰特罗（FF/UMEC/VI）三联疗法与其他疗法治疗慢性阻塞性肺疾病的网络荟萃分析”

Adv Ther. 2023 May;40(5):2549-2555. doi: 10.1007/s12325-023-02491-4. Epub 2023 Apr 1.

A Response to: Letter to the Editor Regarding "Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Triple Therapy Compared with Other Therapies for the Treatment of COPD: A Network Meta-analysis".对《致编辑的信：关于“糠酸氟替卡松/乌美溴铵/维兰特罗（FF/UMEC/VI）三联疗法与其他疗法治疗慢性阻塞性肺疾病的网络荟萃分析”》的回应

Adv Ther. 2023 May;40(5):2556-2561. doi: 10.1007/s12325-023-02495-0. Epub 2023 Apr 1.

Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Triple Therapy Compared with Other Therapies for the Treatment of COPD: A Network Meta-Analysis.糠酸氟替卡松/乌美溴铵/维兰特罗（FF/UMEC/VI）三联疗法与其他 COPD 治疗药物的比较：一项网状荟萃分析。

Adv Ther. 2022 Sep;39(9):3957-3978. doi: 10.1007/s12325-022-02231-0. Epub 2022 Jul 17.

Fluticasone Furoate/Umeclidinium/Vilanterol Initiation Following a COPD Exacerbation: Benefits of Prompt Initiation on COPD Outcomes.糠酸氟替卡松/乌美溴铵/维兰特罗起始治疗 COPD 加重：早期起始治疗对 COPD 结局的获益。

Adv Ther. 2024 Dec;41(12):4557-4580. doi: 10.1007/s12325-024-02999-3. Epub 2024 Oct 25.

Cost-effectiveness analysis of fluticasone furoate/umeclidinium bromide/vilanterol and umeclidinium bromide/vilanterol in the management of moderate and severe COPD in China.氟替卡松/乌美溴铵/维兰特罗与乌美溴铵/维兰特罗在中国中重度 COPD 管理中的成本效果分析。

Respir Med. 2024 May;226:107632. doi: 10.1016/j.rmed.2024.107632. Epub 2024 Apr 16.

Comparative Effectiveness of Fluticasone Furoate/Umeclidinium/Vilanterol and Budesonide/Glycopyrrolate/Formoterol Fumarate among US Patients with Chronic Obstructive Pulmonary Disease.糠酸氟替卡松/乌美溴铵/维兰特罗与布地奈德/格隆溴铵/富马酸福莫特罗在美国慢性阻塞性肺疾病患者中的疗效比较

Adv Ther. 2025 Feb;42(2):1131-1146. doi: 10.1007/s12325-024-03088-1. Epub 2024 Dec 28.

A systematic review with meta-analysis of fluticasone furoate/vilanterol combination for the treatment of stable COPD.糠酸氟替卡松/维兰特罗联合用药治疗稳定期慢性阻塞性肺疾病的系统评价及荟萃分析

Pulm Pharmacol Ther. 2017 Feb;42:1-6. doi: 10.1016/j.pupt.2016.11.003. Epub 2016 Nov 15.

Bayesian or frequentist: there is no question when comparing single-inhaler triple therapies via network meta-analysis. Focus on fluticasone furoate/umeclidinium/vilanterol fixed-dose combination in chronic obstructive pulmonary disease.贝叶斯或频率派：通过网络荟萃分析比较单吸入器三联疗法时，无需质疑。重点关注糠酸氟替卡松/乌美溴铵/维兰特罗固定剂量复方制剂在慢性阻塞性肺疾病中的应用。

Expert Rev Respir Med. 2023 Dec;17(12):1273-1283. doi: 10.1080/17476348.2024.2316167. Epub 2024 Feb 16.

24-Hour Serial Spirometric Assessment of Once-Daily Fluticasone Furoate/Umeclidinium/Vilanterol Versus Twice-Daily Budesonide/Formoterol in Patients with COPD: Analysis of the FULFIL Study.24 小时连续肺量测定评估 COPD 患者中每日一次氟替卡松乌美溴铵/维兰特罗与每日两次布地奈德/福莫特罗的疗效：FULFIL 研究分析。

Adv Ther. 2020 Dec;37(12):4894-4909. doi: 10.1007/s12325-020-01496-7. Epub 2020 Oct 3.

Population Pharmacokinetic Analysis of Fluticasone Furoate/Umeclidinium Bromide/Vilanterol in Patients with Chronic Obstructive Pulmonary Disease.慢性阻塞性肺疾病患者中糠酸氟替卡松/乌美溴铵/维兰特罗的群体药代动力学分析。

Clin Pharmacokinet. 2020 Jan;59(1):67-79. doi: 10.1007/s40262-019-00794-w.

本文引用的文献

Effect of Recent Exacerbation History on the Efficacy of Once-Daily Single-Inhaler Fluticasone Furoate/Umeclidinium/Vilanterol Triple Therapy in Patients with Chronic Obstructive Pulmonary Disease in the FULFIL Trial.FULFIL 试验中近期加重史对慢性阻塞性肺疾病患者每日一次氟替卡松乌美溴铵维兰特罗三联治疗疗效的影响。

Int J Chron Obstruct Pulmon Dis. 2022 Sep 1;17:2043-2052. doi: 10.2147/COPD.S367701. eCollection 2022.

Good Publication Practice (GPP) Guidelines for Company-Sponsored Biomedical Research: 2022 Update.良好的出版实践（GPP）指南：公司赞助的生物医学研究：2022 更新版。

Ann Intern Med. 2022 Sep;175(9):1298-1304. doi: 10.7326/M22-1460. Epub 2022 Aug 30.

Prognostic risk factors for moderate-to-severe exacerbations in patients with chronic obstructive pulmonary disease: a systematic literature review.慢性阻塞性肺疾病患者中重度加重的预后危险因素：系统文献回顾。

Respir Res. 2022 Aug 23;23(1):213. doi: 10.1186/s12931-022-02123-5.

Comparing the Efficacy and Safety Profile of Triple Fixed-Dose Combinations in COPD: A Meta-Analysis and IBiS Score.比较慢性阻塞性肺疾病三联固定剂量组合的疗效和安全性：一项荟萃分析和IBiS评分

J Clin Med. 2022 Aug 1;11(15):4491. doi: 10.3390/jcm11154491.

Adv Ther. 2022 Sep;39(9):3957-3978. doi: 10.1007/s12325-022-02231-0. Epub 2022 Jul 17.

International Differences in the Frequency of Chronic Obstructive Pulmonary Disease Exacerbations Reported in Three Clinical Trials.三项临床试验报告的慢性阻塞性肺疾病加重频率的国际差异。

Am J Respir Crit Care Med. 2022 Jul 1;206(1):25-33. doi: 10.1164/rccm.202111-2630OC.

Concepts and emerging issues of network meta-analysis.网络荟萃分析的概念和新问题。

Korean J Anesthesiol. 2021 Oct;74(5):371-382. doi: 10.4097/kja.21358. Epub 2021 Sep 23.

Comparisons of Efficacy and Safety between Triple (Inhaled Corticosteroid/Long-Acting Muscarinic Antagonist/Long-Acting Beta-Agonist) Therapies in Chronic Obstructive Pulmonary Disease: Systematic Review and Bayesian Network Meta-Analysis.三种（吸入皮质激素/长效毒蕈碱拮抗剂/长效β-激动剂）疗法治疗慢性阻塞性肺疾病的疗效和安全性比较：系统评价和贝叶斯网络荟萃分析。

Respiration. 2021;100(7):631-643. doi: 10.1159/000515133. Epub 2021 May 10.

Efficacy and Safety of Budesonide/Glycopyrronium/Formoterol Fumarate versus Other Triple Combinations in COPD: A Systematic Literature Review and Network Meta-analysis.布地奈德/格隆溴铵/富马酸福莫特罗与其他三联复方制剂治疗 COPD 的疗效和安全性：系统文献评价和网络荟萃分析。

Adv Ther. 2021 Jun;38(6):3089-3112. doi: 10.1007/s12325-021-01703-z. Epub 2021 Apr 30.

Efficacy of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Versus Other Inhaled Corticosteroid/Long-Acting Muscarinic Antagonist/Long-Acting β-Agonist (ICS/LAMA/LABA) Triple Combinations in COPD: A Systematic Literature Review and Network Meta-analysis.布地奈德/格隆溴铵/富马酸福莫特罗干粉吸入剂（BGF MDI）对比其他吸入性皮质类固醇/长效毒蕈碱拮抗剂/长效β激动剂（ICS/LAMA/LABA）三联复方制剂治疗 COPD 的疗效：系统文献评价和网络荟萃分析。

Adv Ther. 2020 Jun;37(6):2956-2975. doi: 10.1007/s12325-020-01311-3. Epub 2020 Apr 25.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验